A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.

Brief description of study

The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD as defined by the Hanifin and Rajka criteria for AD History of AD for 1 year. AD involvement of 550% treatable body surface area at screening and at baseline Procedures include labs, skin swabs, biopsies, EKG, subject questionnaires (excluding scalp).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Medical Research
  • Age: - 99 Years
  • Gender: All


Updated on 17 May 2022. Study ID: 832268

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center